These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 35123932)

  • 1. The incidence of resistance-associated variants to NS5A in HCV subtypes 1a and 1b in Taiwan.
    Tsai MC; Hung CH; Lu SN; Wang JH; Chen CH; Kee KM; Chang KC; Chao TL; Hu TH
    Biomed J; 2021 Dec; 44(6 Suppl 1):S126-S131. PubMed ID: 35123932
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HCV NS5A resistance-associated variants in a group of real-world Japanese patients chronically infected with HCV genotype 1b.
    Hirotsu Y; Kanda T; Matsumura H; Moriyama M; Yokosuka O; Omata M
    Hepatol Int; 2015 Jul; 9(3):424-30. PubMed ID: 25791176
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatitis C virus (HCV) genotype 1 NS5A resistance-associated variants are associated with advanced liver fibrosis independently of HCV-transmission clusters.
    Parczewski M; Kordek J; Janczewska E; Pisula A; Łojewski W; Socha Ł; Wawrzynowicz-Syczewska M; Bociąga-Jasik M; Szymczak A; Cielniak I; Siwak E; Mularska E; Aksak-Wąs B; Urbańska A; Lübke N
    Clin Microbiol Infect; 2019 Apr; 25(4):513.e1-513.e6. PubMed ID: 29981869
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pre-Existing HCV Variants Resistant to DAAs and Their Sensitivity to PegIFN/RBV in Chinese HCV Genotype 1b Patients.
    Zhang Y; Cao Y; Zhang R; Zhang X; Lu H; Wu C; Huo N; Xu X
    PLoS One; 2016; 11(11):e0165658. PubMed ID: 27812165
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of Resistance-Associated NS5A Mutations in Hepatitis C Virus on Viral Production and Susceptibility to Antiviral Reagents.
    Nitta S; Asahina Y; Matsuda M; Yamada N; Sugiyama R; Masaki T; Suzuki R; Kato N; Watanabe M; Wakita T; Kato T
    Sci Rep; 2016 Oct; 6():34652. PubMed ID: 27703205
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of Pre-existing NS5A-L31 or -Y93H Minor Variants on Response Rates in Patients Infected with HCV Genotype-1b Treated with Daclatasvir/Asunaprevir.
    Hernandez D; Yu F; Huang X; Kirov S; Pant S; McPhee F
    Adv Ther; 2016 Jul; 33(7):1169-79. PubMed ID: 27287851
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-life prevalence of resistance-associated variants against non-structural protein 5A inhibitors and efficiency of Daclatasvir + Asunaprevir therapy in Korean patients with genotype 1b hepatitis C.
    Yu JH; Lee JI; Lee KS; Kim JK
    Virol J; 2017 Aug; 14(1):164. PubMed ID: 28836992
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NS5A resistance-associated variants undermine the effectiveness of ledipasvir and sofosbuvir for cirrhotic patients infected with HCV genotype 1b.
    Ogawa E; Furusyo N; Nomura H; Dohmen K; Higashi N; Takahashi K; Kawano A; Azuma K; Satoh T; Nakamuta M; Koyanagi T; Kato M; Shimoda S; Kajiwara E; Hayashi J;
    J Gastroenterol; 2017 Jul; 52(7):845-854. PubMed ID: 27913920
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence of hepatitis C virus (HCV) variants resistant to NS5A inhibitors in naïve patients infected with HCV genotype 1 in Tunisia.
    Aissa Larousse J; Trimoulet P; Recordon Pinson P; Tauzin B; Azzouz MM; Ben Mami N; Cheikh I; Triki H; Fleury H
    Virol J; 2015 Jun; 12():84. PubMed ID: 26047611
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Consideration of Viral Resistance for Optimization of Direct Antiviral Therapy of Hepatitis C Virus Genotype 1-Infected Patients.
    Dietz J; Susser S; Berkowski C; Perner D; Zeuzem S; Sarrazin C
    PLoS One; 2015; 10(8):e0134395. PubMed ID: 26317755
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Naturally occurring resistance mutations to inhibitors of HCV NS5A region and NS5B polymerase in DAA treatment-naïve patients.
    Paolucci S; Fiorina L; Mariani B; Gulminetti R; Novati S; Barbarini G; Bruno R; Baldanti F
    Virol J; 2013 Dec; 10():355. PubMed ID: 24341898
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resistance-associated variants in HCV subtypes 1a and 1b detected by Ion Torrent sequencing platform.
    Gaspareto KV; Ribeiro RM; de Mello Malta F; Gomes-Gouvêa MS; Muto NH; Romano CM; Mendes-Correa MC; Carrilho FJ; Sabino EC; Rebello Pinho JR
    Antivir Ther; 2016; 21(8):653-660. PubMed ID: 27314166
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of glecaprevir and pibrentasvir treatment for genotype 1b hepatitis C virus drug resistance-associated variants in humanized mice.
    Osawa M; Uchida T; Imamura M; Teraoka Y; Fujino H; Nakahara T; Ono A; Murakami E; Kawaoka T; Miki D; Tsuge M; Hiramatsu A; Abe-Chayama H; Hayes CN; Makokha GN; Aikata H; Ishida Y; Tateno C; Miyayama Y; Hijikata M; Chayama K
    J Gen Virol; 2019 Jul; 100(7):1123-1131. PubMed ID: 31199224
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Naturally occurring HCV NS5A/B inhibitor resistance-associated mutations to direct-acting antivirals.
    Nguyen LT; Hall N; Sheerin D; Carr M; De Gascun CF;
    Antivir Ther; 2016; 21(5):447-53. PubMed ID: 26789637
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interferon lambda 4 genotypes and resistance-associated variants in patients infected with hepatitis C virus genotypes 1 and 3.
    Peiffer KH; Sommer L; Susser S; Vermehren J; Herrmann E; Döring M; Dietz J; Perner D; Berkowski C; Zeuzem S; Sarrazin C
    Hepatology; 2016 Jan; 63(1):63-73. PubMed ID: 26406534
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comprehensive Screening for Naturally Occurring Hepatitis C Virus Resistance to Direct-Acting Antivirals in the NS3, NS5A, and NS5B Genes in Worldwide Isolates of Viral Genotypes 1 to 6.
    Patiño-Galindo JÁ; Salvatierra K; González-Candelas F; López-Labrador FX
    Antimicrob Agents Chemother; 2016 Apr; 60(4):2402-16. PubMed ID: 26856832
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence of polymorphisms with significant resistance to NS5A inhibitors in treatment-naive patients with hepatitis C virus genotypes 1a and 3a in Sweden.
    Lindström I; Kjellin M; Palanisamy N; Bondeson K; Wesslén L; Lannergard A; Lennerstrand J
    Infect Dis (Lond); 2015 Aug; 47(8):555-62. PubMed ID: 25851241
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The clinical features of patients with a Y93H variant of hepatitis C virus detected by a PCR invader assay.
    Kan T; Hashimoto S; Kawabe N; Murao M; Nakano T; Shimazaki H; Nakaoka K; Ohki M; Takagawa Y; Kurashita T; Takamura T; Yoshioka K
    J Gastroenterol; 2016 Jan; 51(1):63-70. PubMed ID: 25904097
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of resistance-associated variant dominancy on treatment in patients with HCV genotype 1b receiving daclatasvir/asunaprevir.
    Ikeda H; Watanabe T; Okuse C; Matsumoto N; Ishii T; Yamada N; Shigefuku R; Hattori N; Matsunaga K; Nakano H; Hiraishi T; Kobayashi M; Yasuda K; Yamamoto H; Yasuda H; Kurosaki M; Izumi N; Yotsuyanagi H; Suzuki M; Itoh F
    J Med Virol; 2017 Jan; 89(1):99-105. PubMed ID: 27329864
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resistance Analyses of Japanese Hepatitis C-Infected Patients Receiving Sofosbuvir or Ledipasvir/Sofosbuvir Containing Regimens in Phase 3 Studies.
    Mizokami M; Dvory-Sobol H; Izumi N; Nishiguchi S; Doehle B; Svarovskaia ES; De-Oertel S; Knox S; Brainard DM; Miller MD; Mo H; Sakamoto N; Takehara T; Omata M
    J Viral Hepat; 2016 Oct; 23(10):780-8. PubMed ID: 27196675
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.